checkmate
pharmaceuticals
reports
second
quarter
financial
results
provides
update
recent
progress
successfully
completed
ipo
august
raising
million
gross
proceeds
track
initiate
planned
new
clinical
trials
melanoma
head
neck
cancer
cambridge
globe
newswire
checkmate
pharmaceuticals
nasdaq
cmpi
checkmate
clinical
stage
biotechnology
company
focused
developing
proprietary
technology
harness
power
immune
system
combat
cancer
today
announced
second
quarter
financial
results
provided
update
recent
progress
exciting
time
company
rapidly
develop
across
multiple
tumor
types
combination
checkpoint
inhibitors
said
barry
labinger
chief
executive
officer
recent
public
offering
positions
us
well
execute
clinical
strategic
plans
including
advancement
towards
registration
melanoma
towards
demonstration
proof
concept
additional
tumor
types
including
head
neck
cancer
track
initiate
key
new
clinical
trials
late
early
recent
progress
august
checkmate
closed
initial
public
offering
shares
common
stock
per
share
including
subsequent
partial
exercise
underwriters
overallotment
option
total
gross
proceeds
approximately
million
deducting
underwriting
commissions
offering
expenses
july
food
drug
administration
granted
fast
track
designation
checkmate
product
candidate
differentiated
receptor
agonist
combination
programmed
death
receptor
blocking
antibody
nivolumab
pembrolizumab
refractory
melanoma
metastatic
melanoma
checkmate
actively
engaging
potential
clinical
sites
remains
track
initiate
three
phase
trials
combining
blockade
late
early
treatment
head
neck
cancer
refractory
melanoma
metastatic
unresectable
melanoma
second
quarter
financial
results
cash
cash
equivalents
cash
cash
equivalents
million
june
excluding
proceeds
ipo
completed
august
cash
cash
equivalents
million
june
excluding
proceeds
ipo
completed
august
research
development
expenses
r
r
expenses
million
quarter
ended
june
compared
million
quarter
ended
june
increase
primarily
attributable
costs
upcoming
clinical
trials
well
manufacturing
process
development
costs
r
expenses
million
quarter
ended
june
compared
million
quarter
ended
june
increase
primarily
attributable
costs
upcoming
clinical
trials
well
manufacturing
process
development
costs
general
administration
expenses
g
g
expenses
million
quarter
ended
june
compared
million
quarter
ended
june
increase
primarily
attributable
expenses
incurred
connection
checkmate
preparation
operating
company
g
expenses
million
quarter
ended
june
compared
million
quarter
ended
june
increase
primarily
attributable
expenses
incurred
connection
checkmate
preparation
operating
company
net
loss
comprehensive
loss
net
loss
comprehensive
loss
million
quarter
ended
june
compared
million
quarter
ended
june
checkmate
pharmaceuticals
checkmate
pharmaceuticals
clinical
stage
biotechnology
company
focused
developing
proprietary
technology
harness
power
immune
system
combat
cancer
checkmate
product
candidate
differentiated
agonist
delivered
biologic
particle
designed
trigger
body
innate
immune
system
attack
tumors
combination
therapies
checkmate
goal
leverage
proprietary
technology
discover
develop
commercialize
transformative
treatments
fight
cancer
information
regarding
checkmate
available
forward
looking
statements
various
statements
release
statements
within
meaning
private
securities
litigation
reform
act
amended
including
words
limited
anticipate
believe
could
expect
estimate
design
goal
intend
may
might
objective
plan
predict
project
target
likely
would
negative
terms
similar
expressions
words
identify
statements
statements
based
upon
current
expectations
involve
risks
changes
circumstances
assumptions
uncertainties
statements
include
regarding
product
candidate
including
development
therapeutic
potential
advancement
clinical
preclinical
pipeline
including
timing
enrollment
results
clinical
trials
expectations
regarding
current
future
interactions
food
drug
administration
fda
impact
ongoing
pandemic
business
operations
clinical
trials
clinical
supply
plans
financial
position
cash
runway
statements
read
guarantee
future
performance
results
may
accurate
indications
performance
results
achieved
statements
subject
risks
uncertainties
including
related
development
product
candidate
including
delays
ongoing
planned
preclinical
clinical
trials
impact
ongoing
pandemic
business
operations
clinical
supply
plans
risks
inherent
drug
development
process
risks
regarding
accuracy
estimates
expenses
timing
development
capital
requirements
need
additional
financing
obtaining
maintaining
protecting
intellectual
property
additional
risks
discussed
sections
titled
risk
factors
management
discussion
analysis
financial
condition
results
operations
prospectus
dated
august
filed
securities
exchange
commission
pursuant
rule
b
securities
act
amended
available
sec
website
checkmate
pharmaceuticals
summary
statements
operations
unaudited
thousands
three
months
ended
june
six
months
ended
june
operating
expenses
research
development
general
administrative
total
operating
expenses
loss
operations
interest
income
change
fair
value
convertible
loan
notes
total
income
expense
net
loss
comprehensive
loss
checkmate
pharmaceuticals
summary
balance
sheets
thousands
unaudited
june
december
cash
cash
equivalents
current
assets
total
assets
current
liabilities
total
liabilities
series
redeemable
convertible
preferred
stock
series
b
redeemable
convertible
preferred
stock
series
c
redeemable
convertible
preferred
stock
total
stockholders
deficit
total
liabilities
redeemable
convertible
preferred
stock
stockholders
deficit
investor
contact
kleem
chaudhary
chief
business
officer
kleem
media
contact
karen
sharma
macdougall
ksharma
